Cutaneous invasive aspergillosis in a patient with glioblastoma receiving long-term temozolomide and corticosteroid therapy

J Infect Chemother. 2017 Apr;23(4):253-255. doi: 10.1016/j.jiac.2016.10.004. Epub 2016 Nov 23.

Abstract

Glioblastoma is an aggressive brain tumor that requires multidisciplinary treatment including adjuvant radiotherapy, chemotherapy, and adjunct corticosteroids. Temozolomide is a commonly used chemotherapy drug and frequently causes lymphocytopenia. We describe the case of a 67-year-old woman with cutaneous invasive aspergillosis who had received long-term temozolomide and corticosteroid therapy for glioblastoma. She presented with multiple indurations, erythema, and purpura, some of which produced purulent discharge, in the anterior abdomen. Extensive intra- or inter-muscular abscesses of the right anterior abdominal wall were also observed. Her absolute lymphocyte counts were 156/μL on admission. Cultures obtained from the wound yielded Aspergillus fumigatus. She was diagnosed with secondary cutaneous invasive aspergillosis, which likely resulted from hematogenous dissemination. Although rare, this case illustrates that temozolomide-induced lymphocytopenia, especially in cases of concomitant corticosteroid use, can be associated with severe invasive aspergillosis.

Keywords: Corticosteroids; Cutaneous invasive aspergillosis; Glioblastoma; Temozolomide.

Publication types

  • Case Reports

MeSH terms

  • Adrenal Cortex Hormones / administration & dosage*
  • Adrenal Cortex Hormones / adverse effects*
  • Aged
  • Aspergillosis / chemically induced*
  • Brain Neoplasms / drug therapy
  • Combined Modality Therapy / methods
  • Dacarbazine / administration & dosage
  • Dacarbazine / adverse effects
  • Dacarbazine / analogs & derivatives*
  • Female
  • Glioblastoma / drug therapy*
  • Humans
  • Skin / microbiology*
  • Temozolomide

Substances

  • Adrenal Cortex Hormones
  • Dacarbazine
  • Temozolomide